Fibrosis  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fibrosis
NCT01508286 / 2010-023669-23: Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark BWG 2014: HEP3002
Aug 2014 - Aug 2014: BWG 2014: HEP3002
Checkmark HEP3002
More
No Longer Available
N/A
Europe, RoW
Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin
Janssen-Cilag International NV
Hepatitis C
 
 
RELIF-C, NCT02865369: Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

Not yet recruiting
N/A
103
RoW
Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks
Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb
Chronic Hepatitis C
12/18
12/22
NCT02230982: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

No Longer Available
N/A
RoW
nintedanib
Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
 
 

Download Options